Jinmiao Lu

7PUBLICATIONS
3CO-AUTHORS
Pharmaceutical delivery technologiesCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 04, 2024
Use of a PK/PD Model to Select Cetagliptin Dosages for Patients with Type 2 Diabetes in Phase 3 Trials.

Jinmiao Lu, Jiahong Zhao, Daosheng Xie

|Sep 19, 2023
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.

Linong Ji, Jinmiao Lu, Leili Gao

|Sep 04, 2023
Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial.

Linong Ji, Jinmiao Lu, Leili Gao

|Jun 16, 2022
Disposition study of the novel dipeptidyl peptidase 4 inhibitor cetagliptin in rats.

Jinmiao Lu, Yan Hao, Fuzhi Zhang

|Dec 29, 2021
A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin.

Jinmiao Lu, Lu Wang, Sufeng Zhou

|Nov 08, 2021
The metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] cetagliptin in healthy volunteers.

Jinmiao Lu, Yicong Bian, Hua Zhang

Pageof 2

Frequent Collaborators

2 joint publications

Linong Ji

2 joint publications

Leili Gao

1 joint publications

Changjiang Ying